Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials

References

• GowerEEstesCBlachSRazavi-ShearerKRazaviHGlobal epidemiology and genotype distribution of the hepatitis C virus infectionJ Hepatol2014611 supplS45S5725086286
   PubMed Web of Science ®Google Scholar
• Médecins du MondeNew Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access2014 Available from: http://hepcoalition.org/IMG/pdf/web_daas_strategies_for_achieving_universal_access_en.pdfAccessed December 14, 2016
   Google Scholar
• AhmadTYinPSaffitzJCardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis CHepatology201562240941625251156
   PubMed Web of Science ®Google Scholar
• WeilerNZeuzemSWelkerMWConcise review: interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infectionWorld J Gastroenterol201622419044905627895394
   PubMed Web of Science ®Google Scholar
• HanDSHahmBRhoHMJangSKIdentification of the protease domain in NS3 of hepatitis C virusJ Gen Virol199576pt 49859939049347
   PubMed Web of Science ®Google Scholar
• WelzelTMDultzGZeuzemSInterferon-free antiviral combination therapies without nucleosidic polymerase inhibitorsJ Hepatol2014611 supplS98S10725443350
   PubMed Web of Science ®Google Scholar
• World Health Organization [webpage on the Internet]Guidelines for the screening care and treatment of persons with chronic hepatitis C infection – Updated version (April 2016) Available from: http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/Accessed December 15, 2016
   Google Scholar
• SatsangiSMehtaMDusejaATanejaSDhimanRKChawlaYDual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis CJ Gastroenterol Hepatol201732485986327624314
   PubMed Web of Science ®Google Scholar
• KwoPGitlinNNahassRSimeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized studyHepatology201664237038026799692
   PubMed Web of Science ®Google Scholar
• LeroyVAngusPBronowickiJPDaclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)Hepatology20166351430144126822022
   PubMed Web of Science ®Google Scholar
• FeldJJJacobsonIMHézodeCASTRAL-1 InvestigatorsSofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infectionN Engl J Med2015373272599260726571066
   PubMed Web of Science ®Google Scholar
• LawitzEMatusowGDeJesusESimeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)Hepatology201664236036926704148
   PubMed Web of Science ®Google Scholar
• PoordadFSchiffERVierlingJMDaclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrenceHepatology20166351493150526754432
   PubMed Web of Science ®Google Scholar
• CurryMPO’LearyJGBzowejNASTRAL-4Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosisN Engl J Med2015373272618262826569658
   PubMed Web of Science ®Google Scholar
• Talavera PonsSBoyerALamblinGManaging drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis CBr J Clin Pharmacol201783226929327530469
   PubMed Web of Science ®Google Scholar
• Micromedex® Solutions [homepage on the Internet]Truven Health Analytics Available from: http://www.micromedexsolutions.com/home/dispatchAccessed December 16, 2016
   Google Scholar
• ButiMCallejaJLLensSSimeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO)Aliment Pharmacol Ther201745346847527896822
   PubMed Web of Science ®Google Scholar
• IsakovVZhdanovKKerseyKEfficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb studyAntivir Ther201621867167827376706
   PubMed Web of Science ®Google Scholar
• FosterGRPiankoSBrownAEfficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infectionGastroenterology2016149614621470
   Web of Science ®Google Scholar
• FosterGRAfdhalNRobertsSKASTRAL-2 Investigators; ASTRAL-3 InvestigatorsSofosbuvir and velpatasvir for HCV genotype 2 and 3 infectionN Engl J Med2015373272608261726575258
   PubMed Web of Science ®Google Scholar
• MizokamiMYokosukaOTakeharaTLedipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialLancet Infect Dis201515664565325863559
   PubMed Web of Science ®Google Scholar
• NelsonDRCooperJNLalezariJPALLY-3 Study TeamAll-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyHepatology20156141127113525614962
   PubMed Web of Science ®Google Scholar
• AfdhalNReddyKRNelsonDRION-2 InvestigatorsLedipasvir and sofosbuvir for previously treated HCV genotype 1 infectionN Engl J Med2014370161483149324725238
   PubMed Web of Science ®Google Scholar
• AfdhalNZeuzemSKwoPLedipasvir and sofosbuvir for untreated HCV genotype 1 infectionN Engl J Med2014370201889189824725239
   PubMed Web of Science ®Google Scholar
• KowdleyKVGordonSCReddyKRION-3 InvestigatorsLedipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisN Engl J Med2014370201879188824720702
   PubMed Web of Science ®Google Scholar
• OmataMNishiguchiSUenoYSofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trialJ Viral Hepat2014211176276825196837
   PubMed Web of Science ®Google Scholar
• ZeuzemSDusheikoGMSalupereRVALENCE InvestigatorsSofosbuvir and ribavirin in HCV genotypes 2 and 3N Engl J Med2014370211993200124795201
   PubMed Web of Science ®Google Scholar
• JacobsonIMGordonSCKowdleyKVPOSITRON StudyFUSION StudySofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsN Engl J Med2013368201867187723607593
   PubMed Web of Science ®Google Scholar
• LawitzEMangiaAWylesDSofosbuvir for previously untreated chronic hepatitis C infectionN Engl J Med2013368201878188723607594
   PubMed Web of Science ®Google Scholar
• Gilead SciencesSafety and efficacy of sofosbuvir plus ribavirin in treatment-naive adults with chronic genotype 1 or 3 HCV infection Available from: https://clinicaltrials.gov/ct2/show/NCT02074514?term=NCT02074514&rank=1. NLM identifier: NCT02074514Accessed December 1, 2016
   Google Scholar
• Gilead SciencesSofosbuvir plus ribavirin administered for either 12 or 24 weeks in treatment-naive and treatment-experienced Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection Available from: https://clinicaltrials.gov/ct2/show/NCT01838590?term=NCT01838590&rank=1. NLM identifier: NCT01838590Accessed December 1, 2016
   Google Scholar
• Gilead SciencesOpen-label study of sofosbuvir + ribavirin with or without peginterferon alfa-2a in subjects with chronic HCV infection who participated in prior Gilead HCV studies Available from: https://clinicaltrials.gov/ct2/show/NCT01625338?term=NcT01625338&rank=1. NLM identifier: NCT01625338Accessed December 1, 2016
   Google Scholar
• HeQFZhangQFZhangDZEfficacy and safety of ribavirin with sofosbuvir plus ledipasvir in patients with genotype 1 hepatitis C: a meta-analysisDig Dis Sci201661113108311727619394
   PubMed Web of Science ®Google Scholar
• GogelaNALinMVWisockyJLChungRTEnhancing our understanding of current therapies for hepatitis C virus (HCV)Curr HIV/AIDS Rep2015121687825761432
   PubMed Web of Science ®Google Scholar
• PolSCorougeMVallet-PichardADaclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real lifeHepat Med20168212627019602
   PubMed Web of Science ®Google Scholar
• GaraNGhanyMGWhat the infectious disease physician needs to know about pegylated interferon and ribavirinClin Infect Dis201356111629163623429551
   PubMed Web of Science ®Google Scholar
• SundaramVKowdleyKVRole of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infectionHepat Med20168758027418860
   PubMedGoogle Scholar
• LeeRKottililSWilsonESofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapyHepatol Int201711216117027928718
   PubMed Web of Science ®Google Scholar
• HézodeCBronowickiJPIdeal oral combinations to eradicate HCV: the role of ribavirinJ Hepatol201664121522526409316
   PubMed Web of Science ®Google Scholar
• HwangYKimWKwonSYYuHMKimJHChoeWHIncidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis CKorean J Intern Med201530679280026552454
   PubMed Web of Science ®Google Scholar
• Höner Zu SiederdissenCMaasoumyBMarraFDrug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohortClin Infect Dis201662556156726611779
   PubMed Web of Science ®Google Scholar
• VermehrenJPeifferKHWelschCThe efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infectionAliment Pharmacol Ther201644885686527549000
   PubMed Web of Science ®Google Scholar
• KaoJHAhnSHChienRNUrgency to treat patients with chronic hepatitis C in AsiaJ Gastroenterol Hepatol Epub20161222
   Google Scholar